



Re: Summary of Formulary Changes Effective October 1, 2026.

Dear Health Partner:

We are dedicated to partnering with you to manage our members' care in the most effective way. The CareSource Pharmacy and Therapeutics (P&T) Committee meets regularly to review the Marketplace Drug Formulary and make updates as necessary.

The P&T Committee met recently to update the Formulary. Please review the tables below to see how the Formulary is changing. Additional information about viewing the full Formulary and drug-specific criteria and policies is found at the end of this notice.

Drugs in this table will be added to the Formulary effective October 1, 2026:

DRUG NAME	FORMULARY TIER	COVERAGE LIMITS
Ozempic (semaglutide) Tablets	2	QL, PA

PA= Prior Authorization

QL= Quantity Limits

ST= Step Therapy

Drugs in this table have had a change in how they are covered. This could include a change in their Formulary tier and/or adding or removing a coverage limit. The details are shown below.

DRUG NAME	COVERAGE CHANGE
Avlayah (tiviclenofusp alfa-eknm)	Experimental & Investigational – Medical Benefit
Diabetic Test Strips	Updated Quantity Limit Rules
Guardian CGM Sensors	Criteria Updated – Medical Benefit
Hemophilia A (Hemlibra)	Policies Updated – Medical Benefit
Hemophilia B (Alprolix)	Policies Updated – Medical Benefit
IV Immune Globulin (Gammagard)	Criteria Updated – Medical Benefit
Loargys (pegzilarginase-nbln)	Experimental & Investigational – Medical Benefit
Tysabri, Tyruko (natalizumab)	Policy Updated – Medical Benefit
SC Immune Globulin (Hizentra, Cutaquig)	Criteria Updated – Medical Benefit
Simplera Sync CGM Sensors	Criteria Updated – Medical Benefit
Sotyktu (deucravacitinib)	Criteria Updated
Voxzogo (vosoritide)	Experimental & Investigational
Wakix (pitolisant)	Age Expansion Review, Criteria Updated



Xyrem, Lumryz (sodium oxybate)	Criteria Updated
Xywav (Oxybate Salts [Calcium, Magnesium, Potassium, and Sodium])	Criteria Updated
Yuwiwel (navepegritide)	Experimental & Investigational – Medical Benefit

Drugs in this table were reviewed by the P&T Committee and will have no changes to their Formulary status. Additional clinical updates are noted below.

DRUG NAME	NOTES
Alpha1-Proteinase Inhibitor (Aralast NP, Glassia, Prolastin C, Zemaira [human])	Annual Review - Medical Benefit
Aldurazyme (laronidase)	Annual Review - Medical Benefit
Aqvesme (mitapivat)	New Drug Review
Buphenyl, Pheburane, Olpruva (sodium phenylbutyrate)	Age Expansion Review
Cardamyst (etripamil)	New Drug Review
Casgevvy (exagamglogene autotemcel)	Annual Review - Medical Benefit
Cosentyx (secukinumab)	Age Expansion Review
Dupixent (dupilumab)	New Indication Review, Age Expansion Review
Elaprase (idursulfase)	Annual Review - Medical Benefit
iDose TR (travoprost)	Annual Review
Imcivree (setmelanotide)	New Indication Review
Iqirvo (elafibranor)	Annual Review
Juxtapid (lomitapide)	Age Expansion Review
Kanuma (sebelipase alfa)	Annual Review - Medical Benefit
Leqvio (inclisiran)	New Indication Review, Age Expansion Review - Medical Benefit
Lerochol (lerodalcibep-liga)	Annual Review
Livdelzi (seladelpar)	Annual Review
Mepsevii (vestronidase alfa)	Annual Review - Medical Benefit
MiniMed Instinct CGM Sensors	New Drug Review
Naglazyme (galsulfase)	Annual Review - Medical Benefit
Neffy (epinephrine spray)	Age Expansion Review
Palynziq (pegvaliase-pqpz)	Age Expansion Review
Praluent (alirocumab)	Annual Review
Ravicti (glycerol phenylbutyrate)	Annual Review
Repatha (evolocumab)	Annual Review



Roctavian (valoctocogene roxaparvovec-rvox)	Archiving Policy
Vimizim (elosulfase alfa)	Annual Review – Medical Benefit
Yartemlea (narsoplimab)	New Drug Review – Medical Benefit
Yuvezzi (carbachol and brimonidine tartrate)	New Drug Review
Zoryve (roflumilast)	Annual Review
Zynteglo (betibeglogene autotemcel)	Annual Review – Medical Benefit

We will provide a list of your CareSource members who are taking any medication upon your request. Please email your request to PharmacyConversionProgram@CareSource.com. Include the medication names and your secure fax number in your request. We will fax you a list of your patients who have been prescribed these medications.

We know patient care is of the utmost importance to you. We have sent a letter to our members who may be negatively impacted of this change. We have recommended that they contact their prescriber if they have questions.

Additional Resources

You can view the **full CareSource Marketplace Drug Formulary** on the Provider pages at **CareSource.com**. Select “Drug Formulary” from the Tools and Resources menu under the Providers drop down. The Drug Formulary page also includes a link to our online Formulary Search Tool.

We recognize each patient is unique, and we appreciate your partnership in transitioning members who may be impacted by the Formulary changes above. We are here to help you with any questions. Call the CareSource Pharmacy Services Department at 833-230-2101. The Pharmacy Department is open Monday through Friday, 8 a.m. to 5 p.m.

Thank you for being a CareSource health partner.

Sincerely,
CareSource RxInnovations

Multi-EXC-P-3633600-V.9